Compare Boston Scientific Corporation (BSX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Annaly Capital Management, Inc. — how do they compare? Boston Scientific Corporation trades at $51.18 (market cap $74.19B), while Annaly Capital Management, Inc. trades at $23.28 (market cap $17.44B). The key difference: Boston Scientific Corporation is far larger — about 4.3× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | NLY | |
|---|---|---|
Market Cap | $74.19B | $17.44B |
Sector | Health | Financials |
52-Week High | $108.14 | $24.40 |
52-Week Low | $42.63 | $20.21 |
Enterprise Value | $86.27B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
NLY trades at $22.91, down 0.56% today, with strong technical momentum showing a bullish moving average signal. The stock demonstrates robust fundamentals with a P/E of 5.59, ROE of 20.66%, and consistent earnings beats in recent quarters. Recent Q2 2026 results exceeded expectations with $0.79 EPS versus $0.75 estimate, supported by growing net interest income and dividend coverage improvements.
Analyst consensus remains positive with a $24.50 price target and 57% buy ratings, though investors should monitor interest rate sensitivity given the REIT's mortgage-focused business model. The 13%+ dividend yield provides income appeal, but funding costs and mortgage market volatility present ongoing risks to book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
